GCTK · Glucotrack, Inc.
$1.16
-0.05 (-4.13%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based upon this review and our current financial condition, we have concluded that substantial doubt exists as to our ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$1.28M
Shares
705,255
Volume · Oct 5
85.23K
Avg daily vol (24 sessions)
3.59M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.21
Open$1.34
Day$1.15–1.34
52W close$1.21–128.40
Avg vol 30d2.9M
Short int97K · 13.7% float · 1.0d
Short vol28%
DataApr 2022–Oct 2026
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$70,016
Trailing 12 months
Net income (TTM)
−$15.95M
Trailing 12 months
Revenue growth YoY
-99.9%
Year over year
Operating margin
1,685.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$1.12M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+913.0%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
13.7%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−93%
below
Price vs 50-day avg
−71%
below
RSI (14)
28
oversold
MACD trend
Positive
52-week position
0%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−64%
trailing
6-month return
−91%
trailing
YTD return
−98%
this year
Relative strength
−103%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $18 — 200d above 50d
Institutional flow
Accumulating
+46% holders QoQ · +9 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
13.70% of float · ▲ +287.2% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
19 holders — near 3-yr high, broad support
Squeeze score
64
elevated · 0–100
Fundamentals
Revenue growth
+2883886%
Y/Y
EPS growth
−99%
Y/Y
Free cash flow
$-15.3M
Quant / Vol
risk profile
Volatility
225%
annualized · 1-yr
Max drawdown
−99%
past year
ATR
38.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−93%
Bearish
Price vs 50-day avg
−71%
Bearish
RSI (14)
28
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $4 › 200d $18 — 200d above 50d
Institutional flow
Accumulating
+46% holders QoQ · +9 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
13.70% of float · ▲ +287.2% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
19 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $1 · 0%
Range high $128
vs 200-day avg -93%
vs 50-day avg -71%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GCTK
this stock
Glucotrack, Inc.
|
$1.28M | — | +2883885.7% | — | 13.7% |
|
ABT
Abbott Laboratories
|
$174.90B | -22.2% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -10.1% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -21.6% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -55.3% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GCTK | -33.5% | -63.6% | -90.8% | -26.2% | -97.9% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -33.3% | -63.1% | -103.0% | -27.1% | -110.8% |